Artwork for podcast The Stock Power Podcast
Biotech Stock Tip: Make the Most of the Novel Drug Rush
Episode 10911th June 2021 • The Stock Power Podcast • Money & Markets
00:00:00 00:22:15

Share Episode

Shownotes

Approved

Just one word caused a stock to rise more than 60% in one day.

It’s what happened earlier this week when the Food and Drug Administration signed off on Biogen Inc.’s (Nasdaq: BIIB) new Alzheimer’s drug Aduhelm.

Pro tip No. 1: I talked about the impact of this specific approval on Biogen and the broader biotech sector in a recent podcast. You can listen to that here.

However, an independent panel of medical experts did not endorse the finding, calling drug trial data “unconvincing.”

Regardless of that criticism, this fast-track special consideration was a huge boost for Biogen’s stock price.

In today’s episode of The Bull & The Bear, chief investment strategist Adam O’Dell, Green Zone Fortunes co-editor Charles Sizemore and I talk about Biogen’s recent approval and how “novel” drugs can give biotech companies a leg up … and give substantial profit to investors.

Be sure to also subscribe to our YouTube channel for more videos like my weekly Marijuana Market Update.

Have something you want us to talk about? Email thebullandthebear@moneyandmarkets.com and give us your thoughts.

Check out moneyandmarkets.com, and sign up for our free newsletters that deliver you the most important and unbiased financial news, commentary, and actionable advice.

Also, follow us on:

Facebook

Twitter

LinkedIn

Chapters